SCHEMBL21484829

SCHEMBL21484829

N#CC(=Cc1ccc(C(=O)O)cc1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 1/20 0.55
KMT2A Q03164 5/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 2/20 0.54
NPC1 O15118 1/20 0.54
MAPT P10636 1/20 0.54
RAB9A P51151 1/20 0.54
LMNA P02545 1/20 0.54
HPGD P15428 1/20 0.52
SCD O00767 1/20 0.51
MAPK1 P28482 1/20 0.51
GSTO1 P78417 1/20 0.50
PARP1 P09874 1/20 0.50
PKM P14618 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
APOBEC3A P31941 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484826 1.00 CSNK2A1 (0.55) CSNK2A1KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL28511010 0.90 MAPT (0.55) KMT2AMEN1NPC1MAPTRAB9A
SCHEMBL28511011 0.90 MAPT (0.55) KMT2AMEN1NPC1MAPTRAB9A
SCHEMBL21484907 0.89 LMNA (0.51) CSNK2A1KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL21484909 0.89 LMNA (0.51) CSNK2A1KMT2ASMN1; SMN2MEN1NPC1
SCHEMBL21484809 0.87 EGFR (0.53) CSNK2A1KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL21484810 0.87 EGFR (0.53) CSNK2A1KMT2ASMN1; SMN2MEN1MAPT
SCHEMBL21484718 0.87 KMT2A (0.59) KMT2ASMN1; SMN2MEN1NPC1MAPT
SCHEMBL21495011 0.86 MAPT (0.59) KMT2AMEN1MAPTRAB9ALMNA
SCHEMBL21484838 0.86 MAPT (0.59) KMT2AMEN1MAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 CSNK2A1 2033/4885KMT2A 805/4885SMN1; SMN2 104/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 CSNK2A1 2033/4885KMT2A 805/4885SMN1; SMN2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.